Clinical Trials
11 trialsNCT04093596 2026-05-13
UNIVERSAL
Allogene Therapeutics
Phase 1 Completed
NCT04722146 2026-05-08
MajesTEC-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04126200 2026-05-06
DREAMM 5
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT07084896 2026-05-06
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT05090566 2026-04-24
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Pfizer
Phase 2 Terminated
NCT05556798 2026-02-24
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05137054 2026-01-22
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Regeneron Pharmaceuticals
Phase 1 Recruiting
NCT07150091 2025-09-02
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT07150104 2025-09-02
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT05573802 2023-10-24
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Hellenic Society of Hematology
Phase 1/2 Recruiting
NCT04171843 2023-09-21
A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
Precision BioSciences, Inc.
Phase 1 Terminated